Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ONCT

Oncternal Therapeutics Inc

Last Close
May 01 • 04:00PM ET
8.25
Dollar change
-0.06
Percentage change
-0.72 		%
Held by: VTI VXF DFAT DFAS DFAC IWM IWO IWC ITOT IWV
Index- P/E- EPS (ttm)-13.43 Insider Own9.78% Shs Outstand2.95M Perf Week-3.45%
Market Cap24.42M Forward P/E- EPS next Y-8.44 Insider Trans3.58% Shs Float2.67M Perf Month-11.00%
Income-39.48M PEG- EPS next Q-2.88 Inst Own14.09% Short Float0.52% Perf Quarter-15.56%
Sales0.79M P/S30.91 EPS this Y20.59% Inst Trans-73.22% Short Ratio1.72 Perf Half Y26.53%
Book/sh10.19 P/B0.81 EPS next Y20.86% ROA-74.93% Short Interest0.01M Perf Year17.86%
Cash/sh11.57 P/C0.71 EPS next 5Y0.00% ROE-86.75% 52W Range5.57 - 13.14 Perf YTD-23.07%
Dividend Est.- P/FCF- EPS past 5Y18.19% ROI-130.74% 52W High-37.21% Beta1.18
Dividend TTM- Quick Ratio6.94 Sales past 5Y-9.91% Gross Margin72.08% 52W Low48.23% ATR (14)0.54
Dividend Ex-Date- Current Ratio6.94 EPS Y/Y TTM20.19% Oper. Margin-5313.89% RSI (14)44.02 Volatility5.69% 6.27%
Employees27 Debt/Eq0.01 Sales Y/Y TTM-47.32% Profit Margin-5029.17% Recom1.50 Target Price30.67
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q22.86% Payout- Rel Volume0.55 Prev Close8.31
Sales Surprise132.03% EPS Surprise-0.81% Sales Q/Q73.68% EarningsMar 07 AMC Avg Volume8.03K Price8.25
SMA20-5.28% SMA50-6.63% SMA2006.14% Trades Volume4,418 Change-0.72%
Date Action Analyst Rating Change Price Target Change
Apr-07-21Initiated Oppenheimer Outperform $14
Feb-23-21Initiated Northland Capital Outperform $21
Today 09:00AM
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-25-24 10:02AM
Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
(Zacks)
Apr-18-24 09:00AM
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
(GlobeNewswire)
Apr-14-24 12:51PM
5 Buy-Rated Stocks with Latest Insider Purchases
(Insider Monkey)
Apr-10-24 04:42PM
10 Underperforming Stocks Insiders are Buying
(Insider Monkey)
09:00AM Loading…
Mar-15-24 09:00AM
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
(GlobeNewswire)
Mar-08-24 10:26AM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Mar-07-24 09:54PM
ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023
(InvestorPlace)
04:01PM
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Feb-29-24 04:05PM
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Feb-06-24 04:30PM
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Feb-01-24 09:00AM
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-08-24 09:00AM
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
(GlobeNewswire) +5.08%
Jan-04-24 09:00AM
Oncternal Therapeutics Announces Reverse Stock Split
(GlobeNewswire) -24.49%
Jan-02-24 09:00AM
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
11:04AM Loading…
Dec-28-23 11:04AM
Oncternal Therapeutics reports patient death in CAR-T dose-escalation study
(FierceBiotech.com) -12.42%
Dec-26-23 09:00AM
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
(GlobeNewswire)
Nov-11-23 11:06AM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-09-23 04:01PM
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
(GlobeNewswire) -9.07%
Nov-02-23 04:05PM
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
(GlobeNewswire)
Oct-26-23 09:00AM
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
(GlobeNewswire)
Oct-25-23 09:00AM
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
(GlobeNewswire)
Oct-05-23 04:01PM
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
(GlobeNewswire)
Sep-07-23 09:00AM
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
(GlobeNewswire)
Aug-10-23 04:01PM
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
(GlobeNewswire) -6.71%
Aug-03-23 04:30PM
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
(GlobeNewswire)
04:05PM
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
(GlobeNewswire)
Jul-26-23 01:30PM
Northland Capital Markets Institutional Investor Conference
(ACCESSWIRE)
Jun-30-23 04:30PM
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-06-23 04:01PM
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
(GlobeNewswire)
05:00PM Loading…
May-31-23 05:00PM
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
(GlobeNewswire)
May-06-23 08:14AM
Oncternal Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line
(Simply Wall St.)
May-04-23 04:01PM
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
(GlobeNewswire)
Apr-27-23 05:00PM
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
(GlobeNewswire) +6.62%
Apr-17-23 06:54AM
Daily Vickers Top Buyers & Sellers for 04/17/2023
(Argus Research) +14.57%
Apr-13-23 05:00PM
Oncternal Therapeutics Participating in Oppenheimer & Co.s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors
(GlobeNewswire)
Apr-03-23 04:01PM
Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025
(GlobeNewswire)
Mar-27-23 09:00AM
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -8.39%
Mar-11-23 03:14AM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-09-23 04:01PM
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire)
Mar-02-23 05:00PM
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire)
Mar-01-23 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-01-23 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-04-23 04:05PM
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors
(GlobeNewswire)
Jan-03-23 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Dec-10-22 03:00PM
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
(GlobeNewswire)
Dec-01-22 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-14-22 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +7.21%
Nov-03-22 04:01PM
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
(GlobeNewswire)
09:05AM
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022
(GlobeNewswire)
Oct-27-22 05:53PM
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results
(GlobeNewswire)
Oct-03-22 05:30PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +8.80%
04:31PM
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma
(GlobeNewswire)
Sep-27-22 09:00AM
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL
(GlobeNewswire)
Sep-23-22 09:00AM
Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
(GlobeNewswire)
Sep-07-22 05:00PM
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
(GlobeNewswire)
Aug-09-22 04:05PM
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
(GlobeNewswire)
Aug-02-22 05:00PM
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results
(GlobeNewswire)
Jul-26-22 07:34AM
The past three years for Oncternal Therapeutics (NASDAQ:ONCT) investors has not been profitable
(Simply Wall St.)
Jul-14-22 04:01PM
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL
(GlobeNewswire)
Jun-10-22 04:30PM
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
(GlobeNewswire) -13.99%
09:00AM
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
(GlobeNewswire)
Jun-02-22 09:00AM
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022
(GlobeNewswire)
Jun-01-22 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.41%
May-26-22 05:15PM
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
(GlobeNewswire)
May-17-22 07:40AM
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
(Simply Wall St.) +12.90%
May-05-22 04:01PM
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
(GlobeNewswire)
May-02-22 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +23.05%
Apr-28-22 05:00PM
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
(GlobeNewswire)
03:02PM
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
(Zacks)
Apr-13-22 08:30AM
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
(GlobeNewswire)
Apr-01-22 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-10-22 04:01PM
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire)
Mar-07-22 05:00PM
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire)
Mar-01-22 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-16-22 10:11AM
Oncternal Therapeutics (NASDAQ:ONCT) investors are sitting on a loss of 75% if they invested a year ago
(Simply Wall St.)
Jan-20-22 04:05PM
Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer
(GlobeNewswire) -5.83%
Jan-19-22 05:38PM
Traverso Chambers Private Wealth Management, LLC Buys WisdomTree U.S. ...
(GuruFocus.com)
Jan-04-22 04:01PM
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
(GlobeNewswire)
Dec-14-21 08:53AM
Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Institutions?
(Simply Wall St.)
Dec-13-21 08:00AM
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
(GlobeNewswire) -7.25%
Dec-01-21 05:00PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -5.08%
Nov-15-21 08:00AM
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
(GlobeNewswire)
Nov-09-21 05:00PM
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
(GlobeNewswire)
Nov-04-21 04:05PM
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
(GlobeNewswire) +6.54%
Nov-03-21 05:00PM
Oncternal Therapeutics Joins Karolinska Institutets NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies
(GlobeNewswire)
Nov-02-21 05:00PM
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
(GlobeNewswire)
Nov-01-21 04:05PM
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.45%
Oct-29-21 08:00AM
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results
(GlobeNewswire)
Oct-27-21 03:03PM
Will Oncternal Therapeutics (ONCT) Report Negative Q3 Earnings? What You Should Know
(Zacks)
Oct-15-21 10:51AM
Companies Like Oncternal Therapeutics (NASDAQ:ONCT) Are In A Position To Invest In Growth
(Simply Wall St.)
Oct-05-21 04:05PM
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Oct-01-21 04:01PM
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-20-21 08:00AM
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
(GlobeNewswire) -7.31%
08:00AM
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
(GlobeNewswire)
Sep-09-21 04:01PM
Oncternal Therapeutics to Participate in September Investor Conferences
(GlobeNewswire)
Sep-01-21 04:01PM
Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance
(GlobeNewswire)
Aug-16-21 01:17PM
Oncternal Therapeutics (NASDAQ:ONCT) pulls back 13% this week, but still delivers shareholders respectable 33% return over 1 year
(Simply Wall St.) -5.69%
Aug-05-21 04:01PM
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
(GlobeNewswire)
Aug-02-21 04:05PM
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wills Robert JamesDirectorApr 08 '24Buy8.963,08627,65510,000Apr 10 08:38 PM
Wills Robert JamesDirectorMar 28 '24Buy8.486,91458,6026,914Apr 01 07:00 PM
HALE DAVID FDirectorFeb 23 '24Buy9.047146,455714Feb 27 05:03 PM
HALE DAVID FDirectorFeb 23 '24Buy9.042662,40529,673Feb 27 05:03 PM
Wills Robert JamesDirectorFeb 23 '24Sale9.049808,8590Feb 27 05:02 PM
Kaufmann Gunnar F.Chief Scientific OfficerJun 14 '23Buy0.363,0001,07994,726Jun 14 04:00 PM
Kaufmann Gunnar F.Chief Scientific OfficerJun 12 '23Buy0.3525,0008,74591,726Jun 14 04:00 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

MIST

Milestone Pharmaceuticals Inc

Last Close
May 01 • 04:00PM ET
1.60
Dollar change
-0.05
Percentage change
-3.03 		%
MIST Milestone Pharmaceuticals Inc daily Stock Chart
Held by: GWX
Index- P/E- EPS (ttm)-1.48 Insider Own3.20% Shs Outstand53.15M Perf Week-3.61%
Market Cap85.04M Forward P/E- EPS next Y-1.54 Insider Trans0.00% Shs Float51.45M Perf Month-11.11%
Income-59.69M PEG- EPS next Q-0.26 Inst Own31.81% Short Float0.84% Perf Quarter0.00%
Sales1.00M P/S85.04 EPS this Y17.27% Inst Trans4.34% Short Ratio1.33 Perf Half Y-32.77%
Book/sh0.50 P/B3.19 EPS next Y-34.35% ROA-79.73% Short Interest0.43M Perf Year-55.80%
Cash/sh1.24 P/C1.29 EPS next 5Y- ROE-143.61% 52W Range1.33 - 4.49 Perf YTD-4.19%
Dividend Est.- P/FCF- EPS past 5Y-7.22% ROI-87.77% 52W High-64.37% Beta1.77
Dividend TTM- Quick Ratio10.11 Sales past 5Y-29.33% Gross Margin40.20% 52W Low20.30% ATR (14)0.12
Dividend Ex-Date- Current Ratio10.11 EPS Y/Y TTM-7.56% Oper. Margin-6141.00% RSI (14)45.29 Volatility8.41% 7.12%
Employees47 Debt/Eq3.09 Sales Y/Y TTM-80.00% Profit Margin-5968.50% Recom1.50 Target Price10.50
Option/ShortYes / Yes LT Debt/Eq3.05 EPS Q/Q-31.98% Payout- Rel Volume0.31 Prev Close1.65
Sales Surprise- EPS Surprise-2.40% Sales Q/Q-100.00% EarningsMar 21 BMO Avg Volume323.80K Price1.60
SMA20-5.21% SMA50-3.99% SMA200-32.25% Trades Volume101,028 Change-3.03%
Date Action Analyst Rating Change Price Target Change
Jun-20-23Downgrade Jefferies Buy → Hold $8 → $4
Apr-22-22Upgrade Piper Sandler Neutral → Overweight $8 → $10
Mar-05-21Initiated H.C. Wainwright Buy $20
Jul-29-20Upgrade Oppenheimer Perform → Outperform $18
Jul-24-20Upgrade Jefferies Hold → Buy
Mar-25-20Downgrade Jefferies Buy → Hold $28 → $3
Mar-24-20Downgrade Piper Sandler Overweight → Neutral $26.50 → $3
Mar-24-20Downgrade Oppenheimer Outperform → Perform
Jun-04-19Initiated Oppenheimer Outperform $32
Jun-03-19Initiated Piper Jaffray Overweight $26.50
Show Previous Ratings
Apr-17-24 08:00AM
Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
(GlobeNewswire)
Apr-08-24 11:36AM
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
(GlobeNewswire)
Apr-03-24 08:00AM
Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
(GlobeNewswire)
Apr-01-24 08:00AM
Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
(GlobeNewswire)
Mar-28-24 07:00AM
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
(GlobeNewswire)
01:53PM Loading…
Mar-21-24 01:53PM
MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023
(InvestorPlace)
07:14AM
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
(GlobeNewswire)
Feb-29-24 04:01PM
Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
(GlobeNewswire) -21.13%
07:00AM
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
(GlobeNewswire)
Feb-28-24 04:37PM
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
(GlobeNewswire)
Feb-26-24 07:00AM
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
(GlobeNewswire) +24.12%
Jan-18-24 01:23PM
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm
(GlobeNewswire)
Jan-16-24 09:35AM
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
(Zacks)
Dec-27-23 11:11AM
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
(Zacks) -5.53%
Dec-26-23 10:55AM
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
(GlobeNewswire) -30.90%
07:00AM Loading…
07:00AM
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
(GlobeNewswire)
Nov-21-23 07:00AM
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
(PR Newswire) +13.16%
Nov-13-23 07:02AM
Milestone Pharmaceuticals: Q3 Earnings Snapshot
(Associated Press Finance) -19.59%
06:57AM
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
(PR Newswire)
Nov-11-23 10:00AM
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
(PR Newswire)
Nov-07-23 07:00AM
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR
(PR Newswire)
Oct-24-23 07:00AM
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
(PR Newswire)
Oct-06-23 07:00AM
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(PR Newswire)
Sep-27-23 07:00AM
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
(PR Newswire)
Sep-05-23 07:00AM
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(PR Newswire)
Aug-10-23 07:56AM
Milestone Pharmaceuticals: Q2 Earnings Snapshot
(Associated Press Finance) +5.77%
07:35AM
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
(PR Newswire)
Aug-08-23 09:55AM
2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More)
(TipRanks) +17.63%
Jun-20-23 07:00AM
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
(PR Newswire)
Jun-10-23 09:40AM
Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38%
(Simply Wall St.)
07:00AM Loading…
Jun-01-23 07:00AM
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
(PR Newswire) -6.09%
May-22-23 07:00AM
Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
(PR Newswire)
May-11-23 07:31AM
Milestone Pharmaceuticals: Q1 Earnings Snapshot
(AP Finance) +8.97%
07:16AM
Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
(PR Newswire)
May-08-23 07:00AM
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate
(PR Newswire) +9.19%
May-01-23 06:02AM
Lorenz Muller Is The Chief Commercial Officer of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) And They Just Picked Up 23% More Shares
(Simply Wall St.)
Apr-21-23 09:23AM
Milestone Pharmaceuticals' (NASDAQ:MIST) investors will be pleased with their decent 75% return over the last three years
(Simply Wall St.)
Apr-12-23 07:00AM
Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
(PR Newswire)
Mar-31-23 10:39AM
Despite recent gains, Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insiders are still down US$91k after purchasing last year
(Simply Wall St.)
Mar-29-23 09:17AM
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
(PR Newswire)
Mar-28-23 07:00AM
Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
(PR Newswire) +10.83%
Mar-06-23 07:00AM
Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia
(PR Newswire) +12.23%
Feb-28-23 07:00AM
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
(PR Newswire)
Jan-16-23 12:00PM
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
(Zacks)
Jan-01-23 08:33AM
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is definitely on the radar of institutional investors who own 33% of the company
(Simply Wall St.)
Dec-13-22 09:35AM
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
(Zacks)
Dec-02-22 02:11PM
Will Milestone Pharmaceuticals (NASDAQ:MIST) Spend Its Cash Wisely?
(Simply Wall St.)
Nov-29-22 07:00AM
Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT
(PR Newswire)
Nov-22-22 07:00AM
Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
(PR Newswire)
Nov-12-22 07:47AM
Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 74% over the last three years
(Simply Wall St.)
Nov-10-22 07:21AM
Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update
(PR Newswire) +9.54%
Nov-07-22 12:13PM
Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022
(PR Newswire) -10.32%
Oct-25-22 07:00AM
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022
(PR Newswire) +8.28%
Oct-22-22 08:21AM
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) recent US$101m market cap decline means a loss of US$6.2k for insiders who bought this year
(Simply Wall St.)
08:05AM
Independent Non-Executive Director Michael Tomsicek Just Bought A Handful Of Shares In Milestone Pharmaceuticals Inc. (NASDAQ:MIST)
(Simply Wall St.)
Oct-20-22 09:35AM
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks
(Zacks) +5.44%
Oct-18-22 06:30PM
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
(Zacks) -9.92%
Oct-17-22 09:14AM
Milestone's stock jumps 25% on positive data for tachycardia treatment
(MarketWatch) -21.67%
09:12AM
Milestone Pharma Stock Surges After Successful Trial For Abnormal Heart Rhythm Candidate
(Benzinga)
06:00AM
Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia
(PR Newswire)
Sep-11-22 03:13PM
Oppenheimer Says Biotech Stocks Look a Bit Brighter Right Now; Here Are 2 Names to Consider
(TipRanks)
Sep-06-22 07:00AM
Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
(PR Newswire)
Aug-10-22 04:15PM
Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update
(PR Newswire)
Jul-24-22 10:28AM
What Type Of Shareholders Own The Most Number of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares?
(Simply Wall St.)
Jun-02-22 07:00AM
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
(PR Newswire)
May-27-22 05:03PM
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(PR Newswire) +6.33%
May-23-22 06:23AM
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
(Simply Wall St.)
May-17-22 07:00AM
Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
(PR Newswire)
May-12-22 07:15AM
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
(PR Newswire) -7.40%
Apr-30-22 09:00AM
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
(PR Newswire)
Apr-15-22 04:41PM
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(PR Newswire)
10:20AM
Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have made a respectable return of 36% over the past year
(Simply Wall St.)
Apr-14-22 07:00AM
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
(PR Newswire)
Mar-24-22 07:20AM
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update
(PR Newswire) +9.28%
Mar-01-22 07:00AM
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
(PR Newswire)
Feb-16-22 07:00AM
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
(PR Newswire) -5.41%
Feb-14-22 01:03PM
Could The Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Ownership Structure Tell Us Something Useful?
(Simply Wall St.)
Jan-04-22 07:00AM
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
(PR Newswire)
Dec-14-21 07:56AM
Milestone Pharmaceuticals (NASDAQ:MIST) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.)
Nov-15-21 07:00AM
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
(PR Newswire) +13.93%
Nov-12-21 07:20AM
Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
(PR Newswire) +8.93%
Nov-11-21 07:00AM
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
(PR Newswire)
Oct-15-21 09:31AM
Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 18% over the last year
(Simply Wall St.)
Sep-22-21 07:00AM
Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
(PR Newswire)
Sep-07-21 07:00AM
Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
(PR Newswire) -5.99%
Aug-16-21 10:58AM
What Kind Of Shareholders Own Milestone Pharmaceuticals Inc. (NASDAQ:MIST)?
(Simply Wall St.)
Aug-11-21 04:18PM
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
(PR Newswire)
Aug-03-21 09:01AM
10 Stocks to Buy According to Neil Shahrestanis Ikarian Capital
(Insider Monkey) -6.56%
May-26-21 07:00AM
Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
(PR Newswire)
May-17-21 01:22PM
Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China
(Benzinga)
07:02AM
Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
(PR Newswire)
07:01AM
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
(PR Newswire)
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.